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Abstract 
Mild cognitive impairment (MCI) is characterized by a level of cognitive impairment that is lower than 
normal for a person's age, but higher functioning than a demented person. In the majority of cases 
people with mild cognitive impairment revert back to normal cognitive functioning. However MCI 
often evolves into other more serious etiologies such as but not limited to: Alzheimer’s, frontotemporal 
dementia, and dementia with Lewy bodies. Much effort has been made in determining the prognosis of 
a person with mild cognitive impairment. While treatment options are still in their exploratory stages 
(much of the work in this area has been fruitless) early intervention is considered to be imperative. 
Evidence does suggest that engaging in cognitively demanding activities (such as reading a book or 
playing a game of chess) can have a protective effect against the symptoms of dementia. Furthermore 
there are dietary changes that are correlated with better outcomes in many of the possible etiologies 
associated with mild cognitive impairment. This effort has led to the creation of sub-type classifications 
of mild cognitive impairment, some of which have been associated with an increased risk for a 
particular etiology. Here in, diagnostic techniques and methods are reviewed including: 
neuropsychological assessment, biomarkers in blood plasma, functional imaging (FDG PET & fMRI), 
Volumetric and morphological imaging (using MRI), dynamical analysis of EEG and MEG data, and 
spontaneous speech analysis. Also explored is the link between mild cognitive impairment and 
depression, as well as the evolution of the construct of MCI.  Through investigation of these techniques 
and areas of interest it becomes clear that mild cognitive impairment is a complex clinical construct 
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Conceptualizing the neuropsychiatric diagnosis “Mild Cognitive Impairment” (MCI) has in the past 
twenty or so years become an increasingly important one to understand. MCI is a somewhat enigmatic 
condition in that it is difficult to detect due to its variable and typically mild—and sometimes 
reversible—presentation. It is critical to understand and detect because MCI may herald a variety of 
more serious neuropsychiatric diseases. A lack of consensus among researchers, theorists, and 
clinicians as to how to conceptualize, assess, and diagnose MCI accounts, somewhat, for its puzzling 
status. A strong conceptualization is elusive because of the myriad possible causes: sometimes transient 
minor cognitive fluctuations and at other times precursor of major cognitive disorder. Most people 
experience some cognitive decline in memory associated with aging so MCI must be clinically 
distinguished from normal changes. What is considered “normal” is determined psychometrically by 
average performance, among considerable variability, on a specific cognitive task. Relying only on 
comparison to average scores on such variables for differential diagnosis runs the risk of failing to 
accurately identify an individual case of clinically critical MCI that may predict development of a 
serious disorder (i.e. differentiating a false negative from a true positive diagnosis). The situation is 
further complicated because within a population being studied education and lifestyle variations exist, 
further confounding interpretation of performance scores (e.g., failing to reveal “silent” decline due to 
cognitive reserve occasioned by greater adaptability associated with exceptional educational 
background). Despite these complications, a quasi-operational definition is emerging, based on 
subjective symptoms of MCI. (See the current Diagnostic and Statistical Manual of Mental Disorders, 
APA, 2013). Still a comprehensive conceptual definition of MCI considering broad etiologies, 
prevalence, sub-types, disease progression, and psychometric methods awaits. 
  Kral (1962) was the first to approach age-related declining memory as “senescent 
forgetfulness.” This can be considered the first attempt to characterize a clinical diagnosis approaching 
what is now called MCI. Building on his work, the National Institute of Mental Health introduced the 
term “age-related memory impairment” (AAMI) by in 1986. This designation improved on the label 
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“senescent forgetfulness” by specifying that the decline in memory was abnormal for the age of the 
individual. However this clinical designation was largely established by comparing memory function in 
older adults to that of younger ones (Peterson, 2008). AAMI, focusing solely on memory, does not 
distinguish other domains of cognitive decline and so the International Psychogeriatric Association 
proposed “age related cognitive decline”. In producing this expanded designation, multiple areas of 
cognition thought to be associated with decline in age were included. Normative values taking into 
account age and education level were also incorporated (Levy, 1994). Other designations and variations 
were proposed before the common term, 'mild cognitive impairment' was accepted as the term of 
choice moving forward. 
 The first major study indicating a level of cognitive impairment that was below normal, but not 
reaching decline associated with dementia came at the end of the 20th century. Using 
neuropsychological evaluation, Peterson (1999) examined the performance of a cohort split into four 
distinct groups: demented, mildly demented, healthy controls, and those classified as having MCI.  
Those in the MCI group were shown to have significantly lower scores than the healthy controls, but 
scored consistently higher than those considered demented. Important clinically, this distinction 
identified people with scores between the healthy group and the mildly demented group. The level of 
impairment in the demented groups was designated using a “clinical dementia rating scale” score: a 
scale from 0-5 with 5 being the most severe score, and those not demented registering as a 0 on the 
scale. Anyone with a score of 1 and above was placed in the demented group; the mildly demented 
group scored between a .5 and a <1. The MCI group was not quite <.5, > 0 (Peterson, 1999).  
  In 2003 an international conference for MCI was convened in Stockholm in order to develop 
criteria for including other forms of cognitive impairment. This lead to the development of clinical sub-
types: amnesiac MCI, and non-amnesiac MCI (Winblad, 2004). Building on this criteria, Peterson 
(2014) developed further categorizations for these sub-types relating to the number of cognitive 
modalities they effect: amnesiac multiple-domain MCI (affects memory and other areas of cognitive 
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function), amnesiac single-domain (affects only memory), non-amnesiac multiple-domain (affects 
multiple domains of cognitive functioning but not memory), and non-amnesiac single-domain (only 
affects one domain of cognitive functioning aside from memory).   
 Mild cognitive impairment has recently been the focus of clinical research, due to its potential 
to develop into more serious conditions.  Much of the motivation behind creating the diagnostic sub-
types is to help clinicians and researchers sort out what variations of cognitive impairment herald 
which etiology.  The most prevalent etiology and the focus of most research is Alzheimer’s dementia 
(AD). AD is the most common etiology of each sub-type with the exception of non-amnesiac MCI with 
multiple domains (Busse, 2006). AD is more commonly an outcome for those MCI patients who suffer 
memory impairment. Progression to AD in the amnesiac MCI subcategory is roughly 10-15% 
(Peterson, 2008).  This, as well as other diagnostic information, was the inspiration for a risk based 
assessment algorithm developed by Peterson (2014) and featured as Figure 1.   
 
Figure 1.Visualization of Peterson's (2014) model of risk based assessment of patient etiology. Multiple 
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diagnostic methods are employed to determine a patient's likelihood for progressing from MCI to AD.                                                                                                                                             
 
 Despite being the most common etiology and the focus of critical clinical research, Alzheimer’s 
is far from the only condition to arise from MCI. The situation is further complicated when considering 
that most cases of MCI end up reverting to normal cognitive function (Paynda, 2016). Very often the 
condition of MCI is temporary, perhaps caused by something treatable like depression or chronic sleep 
deprivation. Nonetheless, it is important to distinguish those cases that will develop into a more serious 
condition. Preemptive treatment options, though currently in developing stages, are evolving fast and 
the need to recognize the condition of MCI before it evolves into something more serious is becoming 
a more pressing issue as an aging population becomes more at risk of developing dementia related 
conditions. 
 In this treatise, Mild Cognitive Impairment is explored in terms of diagnostic approaches 
emanating from neuropsychological assessment, functional and connectomic imaging, bio-markers, 
morphological study, spontaneous speech analysis, and the dynamical systems analysis of EEG/MEG 
data. The conceptualization and examination of MCI through the multiple lenses of diagnostic methods 
reveals an implacable and dynamic condition that may be the most powerful early diagnostic challenge 
for determining the direction of early interventions for potentially serious neurodegenerative 
conditions. Mild cognitive impairment is a clinical condition that arises from a variety of physiological, 
psychological, and life style conditions. The condition is sometimes an early warning signal of a 
serious condition and at other times the result of a reversible passing circumstance. As MCI becomes 
understood in greater depth, it will continue to be broken down into distinct variations as we further 
understand how to recognize the early presentation of etiological conditions. This process has already 
begun in the form of sub-type classification. This will here-to-for, as in many areas of scientific inquiry, 
be an interdisciplinary effort. This paper establishes historical perspective, explains current state-of-art 
clinical and technological tools, and looks into future directions for gaining greater diagnostic clarity 
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and treatment interventions. 
                   
Neuropsychological assessment 
 
Until recently the most common neuropsychological assessment tools used to detect MCI were those 
developed to detect AD. These tools were designed to detect much more dramatic fluctuations in 
cognitive ability than are present in MCI. Neuropsychological tests are those designed to assess the 
condition of the brain through noninvasive tasks meant to engage particular modalities of cognition.  
While more sophisticated cognitive assessments are sensitive enough to detect MCI, these tools are too 
time consuming to be performed routinely in a clinic for large numbers of patients. Until very recently 
the Mini Mental State Examination (MMSE) was the closest thing clinicians had to a quick and easy 
way to test for MCI. The MMSE is brief and samples multiple domains of cognitive ability such as 
episodic memory, personal orientation, and visuospatial ability. The patient is given a number of tasks, 
such as being asked to count back from 100 by 7s or what is the date and then a score based on their 
performance of these tasks (Nassredine, 2005). There were other competing assessment tools that 
performed somewhat better than the MMSE in detecting, MCI, such as the Short Test of Mental Status 
(STMS). The STMS was more sensitive (in detection of MCI) than the MMSE when both were tested 
against one another in controlled trials (Taing-Wai, 2003). (Sensitivity refers to a test's ability to detect 
a particular condition.)  
 More recently better tools have been developed. The Montreal Cognitive Assessment (MoCA), 
for instance, has been shown to be significantly more sensitive and comparable in specificity (ability to 
distinguish between conditions) to the MMSE. In a comparison study: the MMSE had 18% sensitivity 
and 100% specificity while the MoCA had 100% sensitivity and 87% specificity when detecting MCI 
in patients already determined to have the condition. It has been suggested that assessments focusing on 
semantic ability, a factor taken into account when producing the MoCA, have a greater potential for 
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detecting MCI (Nassredine, 2005).  
 As mentioned above, the focus of clinical interest has primarily been on assessing MCI as a 
precursor to Alzheimer’s dementia. However, effort has been made to adapt neuropsychological 
evaluations to also distinguish among other possible etiologies. This undertaking has largely been in the 
form of distinguishing sub-types. In some cases this involves focusing attention on one domain of 
evaluation. Patients with amnesiac MCI are considered more likely to convert to Alzheimer’s disease if 
they present with more severe memory impairment (Peterson, 2008). When compared to controls, 
subjects with single domain non-amnesiac MCI mainly showed deficits in executive function when 
assessed using the Trail B test (Diniz, 2008). Subjects with MCI as well as vascular disease were 
shown to perform worse than subjects with only MCI without vascular disease in domains of speed, 
attention, and executive function (Norldund, 2007). Exploration of this kind contributes to developing 
tests that are better able to distinguish the nature of a case of MCI and to predict the future outcome of 
a patient. This allows for preemptive treatment for that particular condition.  
   There have been some attempts to build on this knowledge by augmenting existing evaluations 
to be more sensitive.  For instance, in the previously mentioned study comparing the MMSE and 
STMS; the STMS was augmented with a more demanding recall component in order to make it more 
sensitive to MCI (Taing-Wai, 2003).  Ravaglia (2005) demonstrated that, in assessing patients 
suspected to have MCI with multiple domains, adding a clock drawing test(CDT) to the MMSE 
increased the sensitivity from 50%-40% (either test's sensitivity respectively) to 75%. This 
augmentation did not increase the sensitivity in other domains. In assessing likelihood of conversion 
one study dispensed with cognitive testing entirely. Combining a clinical dementia  rating (CDR)  and a 
questionnaire pertaining to judgment and activities asked of an informant, researchers predicted 
conversion correctly in 88.6% of cases examined (Daly et al, 2000). Despite this progress, 
neuropsychological evaluations such as the MMSE are reportedly lacking in their consistent ability to 
distinguish between MCI sub-types (Diniz, 2008). More research is needed to develop evaluations 
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sensitive enough to distinguish between sub-types.   
 
Depression in Mild Cognitive Impairment 
The connection between depression and mild cognitive impairment has been an interesting and varied 
investigation. Much of the research has focused on the prevalence of depression among those who 
exhibited MCI. Panza (2010) found that prevalence of depression in those with MCI was about 44% in 
hospitalized cases (hospitalized for various reasons) and 15.7% of those in the normal population. This 
disparity could be attributed to selection criteria hospitalized patients being more likely to be 
depressed. Another area of interest concerning depression in MCI is whether or not it increases the risk 
of conversion (to AD).  Modrego (2004) followed a cohort of those diagnosed with amnesiac MCI for a 
period of 3 years. Of 114 in the cohort: 59 developed dementia, 35 (85%) of that group were diagnosed 
as having depression before conversion. It has been suggested that perhaps depression could result in 
MCI, but inquiry into this question is inconclusive (Defranesco, 2008). It is known, however, that 
depression can result in some cognitive impairment. Elderkin (2007) showed that verbal recall and set 
maintenance scores from neuropsychological evolution could when compared, distinguish between 
healthy controls and those with minor & major depression, as well as distinguishing between those 
groups.  Furthermore, executive function measures could separate those with minor depression from 
healthy controls (Elderkin, 2007).  If depression were a cause of MCI this could potentially address the 
issue of remission. The most common outcome of MCI is, after all, reversion back to normal cognition 
(Petersen, 2008) and depression is normally a treatable condition.    
Bio-markers 
Investigation of the various underlying pathological outcomes associated with MCI reveals certain 
biological changes or trends that appear consistently across many etiologies. Some examples are: 
structural changes of specific brain areas (increase or decrease in size), reduced metabolism of specific 
brain areas(as seen with fMRI & FDG PET), white matter changes in conectoemic pathways(Le Bihan, 
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2001), and most notably the accumulation of miss-folded proteins into extra cellular plaques and 
intracellular neurofibulary tangles(Braak A. & Braak E. 1994).  Various techniques and technologies 
have been adapted and utilized in the investigation of these associated phenomena. Many of them, 
despite a lot of progress, remain unreliable and/or expensive to utilize. Baring these concerns in mind, 
the National Institute of Aging has issued general guidelines on what constitutes an appropriate bio-
marker for Alzheimer's Dementia (AD) the most common disease to arise out of MCI as well as one 
that shares many biological features with other etiologies associated with MCI, (Frank et al., 2003; The 
Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute 
on Aging Working Group, 1998). Ideal bio-markers for AD should: 1) detect the fundamental central 
nervous system pathophysiology of AD and be validated in confirmed  neuropathological cases, 2) 
have a diagnostic sensitivity >85% for detecting AD and a specificity >75% for distinguishing between 
other dementias, 3) should detect any beneficial effects of disease modifying therapy, 4) be reliable, 
reproducible, non-invasive, simple to perform, and inexpensive, and 5) be confirmed by at least two 
independent studies conducted by qualified investigators with the results published in peer-reviewed 
journals (Franks et al., 2003). Not every bio-marker will live up to this exacting criteria, which 
highlights the amount of work still needed in this field. 
 
Amyloid beta/tau proteins 
Amyloid neuritic plaques and neurofibrillary tangles are the two key physical elements of Alzheimer’s 
disease (Selkoe, 1994b). Amyloid neuritic plaques, found outside the cell, are composed primarily of 
two amyloid beta (Aβ) proteins:  Aβ 1-40 (containing 40 amino acids) and Aβ1-42 (containing 42 
amino acids (Selkoe, 1994a). Neurofibrillary tangles found inside the cell are composed of errant tau-
proteins that have formed hyperphosphorylated helical structures (Ihara et al, 1986). In a postmortem 
study involving 83 brains diagnosed as exhibiting signs of AD, neuritic plaques and neurofibrillary 
tangles were found present in different areas of the brain corresponding to different intensities of 
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cognitive impairment. Roughly the more impaired an individual the more dispersed the plagues and 
tangles. The stages can be thought of as a score ranging from 0 to VI each stage representing plagues 
and tangles in more areas of the brain (Braak H. & Braak E., 1991).  The early areas affected are the 
entorhinal cortex and hippocampal areas with later stages affecting higher cortical regions (see figure 
2). MCI patients have a high variability of Braak scores. This metric is thought to be most useful when 
applied to cases of MCI that affect memory, such as amnesiac MCI (Stephen, 2012). 
 
 
Figure 2. Distribution of amyloid beta plaques and neurofibrulary tangles at different stages of 
Alzheimer’s dementia (Braak E. & Braak A., 1991)  
 
 Both Aβ and Tau proteins have normal healthy functions in the central nervous system and can 
be found ordinarily in the cerebral spinal fluid. Examining fluctuations in the presence of these proteins 
can potentially reveal the underlying pathology of the brain. Low levels of Aβ1-40 and Aβ 1-42 as well 
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as high levels of Tau protein have been shown to be associated with AD   ( Andreasen et al., 2001; 
Gloeckner et al., 2008; Sjogren et al., 2000 ). Likewise the level of Aβ 1-42 has been shown to rapidly 
decline in cases of MCI (Andreason et al., 2001).  In a meta-analysis of 17 studies examining CSF 
levels of Aβ 1-42 and 34 studies of CSF levels of Tau protein, Aβ1-42 proteins were found to be 
significantly higher and Tau proteins were found to be significantly lower in patients with AD 
(Sunderland et al., 2003). Low Aβ1-42 levels are also seen in other dementias such as frontotemporal 
dementia and dementia with Lewy bodies (Gloeckner et al., 2008), two potential etiologies of MCI. 
This makes CSF analysis a potential diagnostic tool for MCI, although the procedure is considered 
highly invasive and requires a level of expertise not widely available enough to be a realistic option.  
 The human body absorbs about 500ml of CSF into the blood each day (Hye et al., 2006) making 
blood plasma a viable, less invasive alternative for assessment of bio-makers related to 
neurodegenerative conditions. Unfortunately, Tau proteins are below the level of concentration to be 
detected in blood plasma (Tang and Kumar, 2008) but some progress has been made with Aβ proteins. 
There are many factors that make it difficult to detect Aβ proteins in the blood including: age, AD 
pathology, liver catabolism, cardiovascular disease and renal excretion (urination) (Lopez et al, 2008). 
Aβ in the blood can be detected using complicated antibody assay techniques (I.E. ELISA) this 
however is much more difficult than in the CSF. Aβ peptide levels in plasma are roughly 10 times 
lower than they are in the CSF and various other proteins in blood plasma can influence immunological 
detection (Kawarebayashi and Shoji, 2008).  Despite these difficulties there has been some progress in 
this area of research. Locascio et al (2008) found in a longitudinal study that low levels of Aβ 1-40 and 
1-42 in the plasma were correlated with cognitive decline. More research is needed in this area before it 
can be utilized in a clinical setting, but eventually Aβ blood plasma levels, once they can be reliably 
detected, could be a reliable and non-invasive way to detect MCI.  
Imaging 
Morphology 
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Magnetic resonance imaging (MRI) utilizes strong magnetic fields and sophisticated mathematics to 
render a detailed three-dimensional image of the brain and other bodily organs. This enables clinicians 
and researchers to analyze changes in the shape, size, and volume of a rendered structure. The 
entorhinal cortex (ERC) and hippocampus are structures in the brain that are among the earliest 
affected by Alzheimer’s dementia (AD) (Braak. E & Braak. A, 1991) see figure 2.  Using MRI it has 
been determined that a reduction in volume in these structures is associated with AD (Jouttonen, 1999).  
Naturally it was assumed that these structures could also be affected in subjects with MCI. Du. A. T. et 
al (2001) determined, using MRI, that there was significant loss in the volume of the ERC and 
hippocampus in people with MCI compared to healthy controls. The loss was not as great when 
compared to that of AD patients. It was also revealed that MCI subjects experienced an overall 
reduction in gray matter and an increase in ventricular volume. Vemuri (2010) in a longitudinal study 
comparing AD & MCI patients with healthy controls found that increasing ventricular volume was 
associated with a worsening decline in cognitive and functional ability. Other studies revealed a loss of 
gray matter not only in the hippocampus, but also in the posterior cingulate gyrus (PCC) and even parts 
of the temporal neocortex (Chetelat G. 2002). Morphological and volumetric MRI assessment is 
emerging as a reliable diagnostic tool for MCI, but there is still work to be done for it to become a 
routine complement to ordinary diagnostic proceedings. While successes thus far are promising, 
volumetric changes are still not completely understood. 
Functional imaging 
Functional magnetic resonance imaging (fMRI) involves overlying the information obtained in an MRI 
of the brain with visual representations of the changes in the charge of hemoglobin: the protein that 
carries oxygen to organs in the body. When oxygen departs from the iron molecule embedded in 
hemoglobin it changes the protein’s charge and this can be tracked by the MRI machine and overlaid 
on the previously rendered three-dimensional image. Simply put this allows researchers to view which 
parts of the brain are using more oxygen. In a typical fMRI study a reference or resting state is assessed 
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and then compared to an activated state (Rombouts, 2005).  The oxygen uptake is observed first in a 
utilized state and then in a state where it is known to be engaged in an action. This is called a blood 
oxygen level-dependent (BOLD) reading.  An increasing area of interest for researchers is so-called 
“deactivations”. There are certain areas in the brain with a high resting state such as: medial frontal, 
medial parietal and posterior cingulate gyrus (Gusnard et al. 2001). Many of these areas are associated 
with some of the later stages of AD (Braak E. Braak A. 1991). These areas, collectively referred to as 
the default mode network, appear to be deactivated when other areas of the brain are active and have 
been associated with perceiving environmental stimuli (Gusnard et al., 2001; Raichle et al., 2001). The 
default mode network has also been associate with retrieving memories and planning behaviors (Binder 
et al, 1999). The default mode network has been shown to be less active in those diagnosed with AD 
(Greicius et al, 2004).  Rombouts (2005) compared 28 individuals with MCI to 18 patients with AD 
and 41 healthy controls. The subjects were given working and episodic memory tasks and fMRI scans. 
Subjects with MCI showed greater deactivation in the default mode areas than controls but not as great 
as AD patients. Another fMRI study comparing healthy controls to MCI and AD patients on memory as 
well as sensory motor tasks it was shown that individuals with MCI and AD did have decreased 
activation of memory related areas such as the hippocampus/medial temporal areas. However sensory 
motor area activation was no different from health controls (Machulda, 2003). This suggests that it is 
not a global decrease in activity but specific to areas related to memory.  
 Positron emission topography (PET) is a method of functional imaging that utilizes radioactive 
tracing agents that release positrons that impact with electrons and upon annihilation release two 511-
keV γ-rays that travel in opposite directions roughly 180 degrees from each other (Newberg,2002).  
Most notable for the study of brains is Fluoro-2-deoxy-D-glucose positron emission tomography (FDG 
PET) or radiologically labeled glucose. Glucose is a sugar molecule broken down and used for energy 
by cells in the body. This allows researchers to use PET scanners to track which part of the brain is 
using more glucose than another which suggests that part of the brain is more active.  
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 FDG-PET scans are an area of interest as a supporting diagnostic tool for various types of 
dementia as well as MCI.  AD patients typically show a deficit of glucose uptake (hypometabolism) in 
the posterior cingulate, pariototemporal cortices and frontal lobes (Masconi, 2005). Frontotemporal 
dementia (FTD) presents with hypometabolism in the frontal lobes early in its presentation, and then 
the parietal and temporal cortices in the more advanced stages of the disease (Deilh-schmid, 2007). 
Patients presenting with dementia with Lewy bodies (DLB) showed hypometabolism in the posterior 
cingulate, perietotemporal and frontal association areas, as well as the occipital cortex predominantly in 
the visual cortex (Minoshima, 2001). It was the presentation of hypometabolism in the visual cortex 
that allowed DLB to be distinguished from AD using FDG PET (Minoshima, 2001). Masconi (2008) 
found that 86% (101 out of 114) MCI patients scanned with FDG PET showed general cortical 
hypometabolism on the level indicating a neurodegenerative disease. In the same study 96 MCI 
patients were found to have hypometabolism in the hippocampus alone while 92 had hypomotabolism 
in the hippocampus as well as the posterior cingulate cortex. Examining the FDG PET neocortical 
profile of a cohort of 114 MCI patients in comparison to other dementias: 29 had patterns similar to 
AD, 8 had patterns that reflected DLB, and 2 had patterns similar to FTD (Masconi, 2008).   
Diffusion tensor imaging 
 One relatively new tool in the arsenal of imaging diagnostic instruments for the brain is diffusion-
tensor imaging (DTI). This process utilizes a powerful MRI machine to track the displacement of water 
molecules. Water molecules like many others are prone to random movement over time, sometimes 
referred to as Brownian motion. In the course of this random motion these molecules will probe their 
encapsulating structures at a level of resolution much smaller than what can be rendered by any 
available imaging device. Therefor tracking the motion and displacement of these molecules reveals 
detailed information about the structures that affect their movement (Le Bihan, 2001). In the case of the 
brain, often this imaging technique is used to assess the structural integrity of white matter fibers  
(Le Bihan, 2001). The fibers that connect distinct areas of the brain are often insulated with segments 
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of what’s called myelin. In the central nervous system these are produced by specialized glial cells 
called oligodendrocytes that wrap themselves around neurons as they grow. These cells maintain the 
integrity of neural potentials (signals) while increasing their speed by as much as 150 times. This 
allows for expedient communication of information between far reaching areas of the brain (Strieder, 
2016).  
 There are several ways to analyze DTI data, the two most commonly applied metrics in the area 
of neurodegenerative diseases are fractional anisotropy (FA) and mean diffusivity (MD). Mean 
diffusivity measures the average-squared displacement of water molecules as well as the present 
obstacles of diffusion (Le Bihan, 2001).  Fractional anisotropy determines the directionality of the fiber 
tracks themselves. Water will move more quickly if they are moving parallel to the structure that 
surrounds them. For instance water in white-matter tracks will move quickly if it is moving along the 
orientation of the fiber track. This allows for the determination of the orientation of the fiber track as 
well as revealing information about their general integrity (Le Bihan, 2001). Numerous studies have 
found abnormal FA and MD readings in AD patients in the corpus callosum, posterior cingulate, and 
the parietal & temporal lobe (Zhang, 2007). Examination of MCI using DTI techniques has met with 
some success but is currently tentative as a diagnostic tool. Fellgiebel (2005) found that MCI cases 
showed a significant reduction in FA values in the posterior cingulum bundle as compared to healthy 
controls. Mean diffusivity MD values were elevated in the left side of the posterior cingulum bundle 
(white matter fibers projecting from the cingulate) in MCI cases compared to healthy controls. 
However MD & FA were not statistically significant in comparing differences to AD (Fellgiebel, 2005).  
In a meta-analysis examining MCI patients Sexton (2010) found significant effect sizes (denoting 
differences in FA values)  in the white matter of the occipital lobe, genu, frontal lobe, splenium, 
temporal lobe, and 4 different regions of the cingulum bundle. Many of these areas are associated with 
the stages of accumulation of amyloid beta plaques and neurofibrillary tangles in AD (Braak A. & 
Braak E., 1991). In that same meta-analysis significant MD effect sizes were found in 6 regions in MCI 
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cases: posterior cingulum, genu of the corpus callosum, temporal white matter, splenium, parietal white 
matter and the hippocampus (Sexton, 2011). Marked progress is being made in the formation of DTI as 
a diagnostic tool. One area worth exploring is correlating DTI measures with scores of 
neuropsychological tests. Some work has been done in this area, for instance: Fellgiebel (2005) showed 
that FA & MD values of the posterior cingulum correlated significantly with delayed verbal recall test 
scores.   
Dynamical systems analysis of EEG/MEG 
An emerging trend among neuroscientists is approaching the brain as a complex nonlinear dynamical 
dissipative system (Stam, 2005). At its essence, this is a recognition that the brain, as a system, has 
emergent qualities and cannot be understood entirely by reductionist, cause-effect means. Reductionism 
in this context refers to examining one part of the brain at a time. Emergence is a causal property of a 
system that cannot be attributed to an individual element of the system (e.g. no part of a cell is alive, 
but in aggregate they form the smallest unit of life). For instance the magnetic waves of the brain, 
detectable by electroencephalograph (EEG) or magnetoencephalogram (MEG) can be thought of as 
emergent properties of the brain as a whole (Stam, 2005). Non-linear systems is a field concerned with 
(among other things) the synchronization of nonlinear complex systems. By way of EEG & MEG it is 
possible to infer the likely degree of synchronicity between discrete brain regions. EEGs record 
different bands corresponding to different frequencies: Delta (3 Hz or below), Theta (3.5-7.5 Hz), 
Alpha 7.5 to 13 Hz), and Beta (faster than 13 Hz). Synchronization within different bands or 
frequencies are associated with different cognitive tasks. For instance synchronization between frontal 
and post central association areas are thought to be associated with working memory (Stam, 2003). 
Different levels of synchronicity are thought to be associated with different conditions. One would 
expect a brain experiencing epileptic seizures to be over synchronized while a sufferer of a 
neurodegenerative condition would have a lower degree of synchronization compared to normal 
functioning people (Stam, 2005). While readings are becoming increasingly consistent for AD, MCI 
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has yet to yield results that are consistently reliable. The issue lies in distinguishing AD from MCI. 
Stam (2003) found that those with AD and MCI showed significantly decreased synchronization 
likelihood across the 14-18 and 18-22 Hz bands as compared to controls. More work is needed to 
develop this field, but the prospects are exciting.         
Speech analysis 
One area of increasing importance is the examination of spontaneous speech analysis in the diagnosis 
of AD and MCI. It has long been known that AD presents with discrepancies in speech such as anomia 
and decreased content in spontaneous speech (Cummings, 1988). Recent efforts have attempted to find 
ways to exploit this phenomena as a way to generate a reliable and non-invasive method of diagnosing 
AD (Lopez-de-Ipiña, 2015). Speech analysis research largely exists in a stage of exploration. An exact 
method of diagnosis or even what to look for has yet to be established. However there has been some 
recent success. Koing (2015) showed that using speech analysis they were able to distinguish healthy 
controls (HC) from MCI cases with roughly 70% accuracy, HC from AD with about 87% accuracy, and 
AD from MCI with approximately 80% accuracy. This ability to distinguish between MCI and AD is an 
especially exciting accomplishment. This technology has the potential to be an invaluable addition to 
existing efforts to render an objective diagnoses cognitive impairment.   
 
Treatment 
 Much of the motivation to accurately diagnose MCI is to have an earlier indication of a more serious 
condition. The idea is that if a condition like AD is detected early, prospective therapies (yet to be 
developed) could be administered to preemptively ameliorate cognitive decline. It has been shown that 
cognitively stimulating activities can have a protective affect against cognitive decline and potentially 
reduce the risk of conversion to AD (Peterson, 2008). Reading a book or playing a game of chess are 
considered cognitively stimulating activities (Peterson, 2008). Additionally, decreased consumption of 
cholesterol, total & saturated fats has been correlated with less cognitive decline (Peterson, 2008). An 
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early indication of something like AD or other dementias would give a person time to make life style 
changes that could lessen the impact of a developing condition. There has been many attempts to 
develop a more decisive intervention, but unfortunately drug trials have seen little in the way of success 
(Petersen, 2007). Much of these difficulties can be attributed to our lack of understanding about the 
MCI construct (Peterson, 2007). As our understanding increases more possibilities for treatment will be 
explored.    
Discussion 
Mild cognitive impairment is a rapidly developing clinical diagnostic construct, attracting researchers 
in disciplines from psychology to applied mathematics. Still, there are gaps in our understanding of 
MCI. The biomarkers we know to be associated with MCI (such as Aβ plaques and neurofibrillary 
tangles) have been examined through a variety of different means. However it is clear especially 
considering the failed attempts at intervention (Peterson, 2007) that there are factors involved to which 
we are unaware. Some scientists are embracing this and taking on more explorative methods of 
research.  For instance some methods in proteomics (the study of proteins), such as mass spectrometry 
allow for an inventory of many different proteins in blood plasma and serum (Song, 2009). This allows 
researchers to explore the physiology of a person with AD or MCI without focusing on just one specific 
bio-marker. Developing areas such as dynamical systems analysis of EEGs or automatic speech 
analysis offer exciting possibilities for the future. One can imagine a time when we know exactly what 
proteins to look for in blood plasma and what aberrations in speech betray an inchoate 
neurodegenerative condition.  In such a time, an app on your phone could alert a person to go see a 
physician long before even minor symptoms develop. Such a time is a long way off. There is much 
more to learn about the diagnoses and especially the, treatment of MCI.  
 As the population ages, MCI is becoming a more important area of research. One area in need 
of much attention is prevalence in the population. MCI has been problematic in this area for a number 
of reasons. One is a lack of consensus in the criteria that make up MCI.  
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 MCI remains a complex construct, even more so after examining the purposed mechanisms and 
theories of its pathology. As is the case with any complex phenomena, unraveling its mysteries will be 
an interdisciplinary endeavor. MCI should not be viewed as a condition unto itself, it is not a cause of 
symptoms. It can be thought of, in many cases, as a transient set of symptoms arrived at for a variety of 
reasons and in the course of a developing prognosis. Future research on MCI should focus on 
understanding the dynamics of the underlying condition. It is in this understanding that we can learn all  
the causes of MCI, for indeed there are more than one and they are not necessarily all related. A smart 
approach would be to make an effort to correlate the presentation of neuropsychological symptoms 
with underlying physiological markers. For instance the effort to associate different cognitive tasks 
with desynchronization of brain regions or to correlate executive function to vascular disease is a step 
in the right direction. Once these connections are made, they can be grouped into clusters of symptoms. 
This process will eventually lead to more distinct and useful subtypes of MCI. Throughout this process 
it is necessary to explore convenient and affordable methods of detecting these physiological 
indicators. It is through this iterative process that MCI will eventually become a useful construct in 
determining the prognosis of its sufferers. MCI in its current form is more appropriately thought of as a 
target for efforts in research than a clinical diagnosis. Put another way MCI is not an answer, it is 
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